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Saccharomyces cerevisiae Tel1 is the ortholog of human ATM
kinase and initiates a cell cycle checkpoint in response to
dsDNA breaks (DSBs). Tel1ATM kinase is activated synergisti-
cally by naked dsDNA and the Mre11-Rad50-Xrs2NBS1 complex
(MRX). A multisubunit protein complex, which is related to
human shelterin, protects telomeres from being recognized as
DSBs, thereby preventing a Tel1ATM checkpoint response. How-
ever, at very short telomeres, Tel1ATM can be recruited and acti-
vated by the MRX complex, resulting in telomere elongation.
Conversely, at long telomeres, Rap1-interacting-factor 2 (Rif2)
is instrumental in suppressing Tel1 activity. Here, using an in
vitro reconstituted Tel1 kinase activation assay, we show that
Rif2 inhibits MRX-dependent Tel1 kinase activity. Rif2 dis-
charges the ATP-bound form of Rad50, which is essential for all
MRX-dependent activities. This conclusion is further strength-
ened by experiments with a Rad50 allosteric ATPase mutant
that maps outside the conserved ATP binding pocket. We pro-
pose a model in which Rif2 attenuates Tel1 activity at telomeres
by acting directly on Rad50 and discharging its activated ATP-
bound state, thereby rendering the MRX complex incompetent
for Tel1 activation. These findings expand our understanding of
the mechanism by which Rif2 controls telomere length.
Telomeres are DNA-protein complexes that define the phys-
ical ends of linear eukaryotic chromosomes. Telomeric DNA is
composed of short, tandem G-rich repeats that extend for
thousands of bases at the 3-ends of chromosomes. Proper
establishment and maintenance of telomeres is essential for
genome stability and cell survival (1, 2). Telomeres progres-
sively shorten as cells divide. Telomere shortening is counter-
acted by telomerase, a reverse transcriptase that synthesizes the
G-rich telomeric repeats de novo (3). Yeast cells and primary
mammalian cells that are unable to maintain telomeres pro-
gress into senescence, which is mediated by a DNA damage–
signaling pathway (4). Telomere-induced senescence underlies
a plethora of human genetic disorders that share short telomere
as a common molecular defect (5, 6). On the other hand, in
humans, the inappropriate elongation of telomere leads to can-
cer predisposition and aids in the survival of cancer cells (7).
In addition to telomerase, telomere DNA repeats are bound
by a set of proteins that assemble into a protective capping
structure called shelterin (8). This DNA-protein structure
serves two important functions. First, it protects chromosome
ends from nucleolytic degradation and from being recognized
as dsDNA breaks (DSBs).3 Improper recognition of chromo-
some ends as DSBs would elicit a DNA-damage checkpoint and
promote repair, which at telomeres could result in telomeric
fusions. Second, shelterin regulates telomere length by control-
ling access of telomerase and its activity (9, 10). The shelterin-
analogous complex in Saccharomyces cerevisiae is composed of
many proteins which include the Rap1-Rif1-Rif2 complex and
the Cdc13-Stn1-Ten1 complex. The Rap1-Rif1-Rif2 protein
complex associates with the double-stranded TG(1–3) repeat
and is a pivotal player in telomere homeostasis (11–13). The
Cdc13-Stn1-Ten1 complex forms RPA-like (replication pro-
tein A) trimeric complex that binds to the single-stranded 3
overhang and prevents its nucleolytic degradation(14, 15). In
addition to these major telomere-associated proteins, there are
other enzymes that mediate both end protection and telomere
length control. Among these are Tel1 checkpoint kinase, the
ortholog of human ATM, and the MRX(N) complex composed
of Mre11, Rad50, and Xrs2 (human NBS1) (16). The Rad50
subunit binds ATP and has weak ATPase activity that is stim-
ulated a few -fold in the presence of dsDNA. Disabling ATP
binding to Rad50 results in a rad50 phenotype (17).
The double-stranded telomeric regions of S. cerevisiae con-
tain extended repetitive arrays of high-affinity Rap1-binding
sites (11, 18, 19). Rap1 also recruits Rif1 and Rif2 to telomeres.
Both of these proteins bind to the C-terminal domain of Rap1,
and this interaction is required for their recruitment(12, 13, 20,
21). Deletion of Rif1 and Rif2 leads to telomere elongation, and
deletion of both has an additive effect. Strains that express a
Rap1 variant lacking the C-terminal domain confer a telomere
phenotype similar to rif1 rif2 double deletion (13). Based on
these genetic observations, current models propose that long
telomeres, by virtue of their size, are able to support the binding
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of an increased number of Rap1-Rif1-Rif2 complexes (Fig. 1A)
(20), leading to an increased repressive effect on telomere elon-
gation. Conversely, short telomeres bind fewer of these repres-
sive complexes and are more frequently elongated. Tethering
Rif1 and Rif2 to telomeres by other means than binding to Rap1
also limits telomere elongation (22, 23). This supports the
model that Rif1 and Rif2, and not Rap1, are responsible for the
repressive effect. The preferential extension of short telomeres
coupled with the restrained elongation of long telomeres main-
tains telomere length homeostasis.
The protein kinase Tel1 coordinates checkpoint activation in
response to DSBs (24). Tel1’s recruitment to DSBs and the sub-
sequent activation of its protein kinase activity depends on
MRX (25). This central three-subunit complex consists of
Mre11 nuclease, Rad50 ATPase, and the auxiliary subunit Xrs2
(NBS1) (26, 27). In addition to its role in DNA break repair, Tel1
is also involved in telomere length regulation (16). Tel1 specif-
ically associates with short telomeres, and tel1 mutants show
a defect in telomerase-mediated telomere elongation (28 –31).
Although the exact mechanism of Tel1-mediated telomere
length regulation is unknown, its kinase activity is essential
because cells expressing kinase-dead Tel1 show similar telom-
ere length defects as tel1 cells (24, 32). Tel1 binding to telom-
eres has been shown to depend on the C-terminal domain of the
Xrs2 subunit of MRX (25). Deletion of any of the subunits of
MRX, or destructive mutation of the ATP-binding site in Rad50
shows the same telomere-shortening phenotype as a tel1
mutant, or a tel1 MRX double mutant (16, 28, 33). This indi-
cates that Tel1 and MRX require its Rad50 ATPase to positively
regulate telomere length in the same pathway.
The mechanism by which Rif2 controls telomere length
remains elusive. Recent studies have suggested that Rif2 atten-
uates the functions of Tel1 and MRX at telomeres. Rif2 inter-
acts with Xrs2 in the same region as Tel1 does, prompting the
model that Rif2 counteracts MRX-dependent recruitment of
Tel1 to telomeres by simple competition (22). Here, we have
studied the role of Rif2 in the MRX-dependent activation of
Tel1 in a reconstituted biochemical system. Our data show that
Rif2 inhibits MRX-dependent stimulation of Tel1, independent
of interaction with Xrs2. A recent study has shown that Rif2
stimulates the ATPase activity of Rad50 (34). We show here
that Rif2 acts directly on Rad50 by discharging its activated
ATP-bound state, thereby making the MRX complex incompe-
tent for Tel1 activation.
Results and discussion
Rif2 inhibits MRX-dependent activation of Tel1 kinase
We have employed an in vitro assay using purified proteins to
examine the potential role that Rif2 plays in regulating the
activities of Tel1 and MRX. Tel1’s physiological substrate is
Rad53, the effector kinase in the cell cycle checkpoint pathway
(35). Phosphorylation of Rad53 was used as a direct readout of
Tel1 kinase activity. We showed previously that individually
MRX or DNA caused a 2- to 3-fold stimulation of Tel1 kinase
activity; however, when both are present, a greatly synergistic
stimulation of Tel1 kinase was observed (36) (Fig. 1B). This
Figure 1. Rif2 inhibits MRX-dependent activation of Tel1 kinase. A, simplified model for the regulatory activity of Rif2. Note that localization of Rif2 to
telomers requires interaction with Rap1 (not shown). B, top, schematic representation of in vitro kinase assay using purified proteins. The mutations in
Rad50(CC48) are near the Zn-binding site. Bottom, standard kinase reactions (see “Experimental procedures”) contained the indicated factors, and either 10
nM Telo-155 or Nat-147 DNA where indicated. C, standard kinase reaction with 30 nM MRX, and either 10 nM Telo-155 or Nat-147 DNA, contained the indicated
concentrations of Rif2. D, quantification of four independent replicates of the assay shown in C. Relative Tel1 activity of the reaction without Rif2 was set to 100
(lane 2). Averages and S.E. are shown. Half-maximal inhibition was observed at 200 –300 nM Rif2.
Rif2 inactivates the ATP form of MRX
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strong stimulation is independent of DNA sequence; both ran-
dom DNA (Nat) and telomeric repeat DNA (Telo) showed a
similar response.
To test whether Rif2 has a function in the MRX-dependent
activation of Tel1, we titrated Rif2 into the complete assay, con-
taining both MRX and DNA (Fig. 1C). Rif2 inhibited Tel1
kinase in this assay, as shown by a reduction in Rad53 phosphor-
ylation, independent of the nature of the DNA sequence (telo-
meric versus nontelomeric (Nat)) (Fig. 1, C and D). We note that
full inhibition of MRX-dependent kinase activity requires high
concentrations of Rif2, suggesting weak interactions with the
complex. Moreover, in our assay, the Rif2-mediated inhibition
is independent of DNA-bound Rap1 (Fig. S1A). In the cell, inhi-
bition at telomeres occurs via the tethering of Rif2 to telomeres
through Rap1. However, Rap1-Rif2 binding is weak (37), sug-
gesting that extended arrays of Rap1-Rif2 may be required for
full inhibition in vivo. This result is consistent with the genetic
observation that Rap1’s requirement for telomere length con-
trol can be bypassed by artificially tethering Rif2 to telomeres
(21). Taken together, these observations support a model that is
based on genetic data, i.e. that Rif2 attenuates the functions of
Tel1 and MRX at telomeres. In a control experiment, we deter-
mined that the Rif2-mediated inhibition is not specific to Tel1’s
physiological phosphorylation target Rad53. A heterologous
substrate, human PHAS-I, also showed severely reduced phos-
phorylation by Tel1 in this assay when Rif2 was added (Fig.
S1B).
The protein kinase activity of Tel1 is required for all Tel1-
mediated transactions, including telomere regulation in vivo
(24, 32). However, the inhibitory activity of Rif2 does not pro-
ceed through Tel1 directly. Rif2 inhibited neither the basal Tel1
kinase activity (not shown) nor the DNA-stimulated Tel1
kinase activity (Fig. S1C). These data suggest that Rif2 inhibi-
tion may proceed through MRX.
The Xrs2 subunit of MRX is dispensable for Rif2’s inhibitory
activity in vitro
Tel1 recruitment to telomeres and dsDNA breaks requires
its association with the C terminus of Xrs2 (25). A C-terminal
truncation of Xrs2 (human NBS1) attenuates MRX function
without affecting the stability of the MRX complex in budding
yeast, fission yeast, and human cells (25, 38 –40). Moreover,
Rif2 interacts with Xrs2 within the same C-terminal region as
Tel1. This has led to the proposal of a model by which Rif2 may
exert its inhibitory role by abrogating the binding of Tel1 to
Xrs2, and thereby to MRX (22). One prediction of this model is
that inhibition depends on Xrs2.
In a recent study, we showed that Rad50 is the critical subunit
of MRX for full activation of Tel1 (36). In addition to DNA and
Rad50, either Mre11 or Xrs2, but not both, is also required.
Thus, both the Mre11-Rad50 and Rad50-Xrs2 pairs, but not the
Mre11-Xrs2 pair, function efficiently in vitro (36). We tested
whether Rif2 inhibited the activation of Tel1 by the different
dimeric pairs of MRX. Rif2 inhibited Tel1 activation by MRX
and by RX, and also by MR lacking Xrs2 (Fig. 2, A and B). These
data suggest that Rif2 enforces its inhibition through the Rad50
subunit, which is the common subunit in all complexes. The
observation of a functional relationship between Rad50 and
Rif2 prompted us to test for their physical interaction. GST-
tagged Rif2 was able to pull down Rad50 with an efficiency
comparable to that of the positive control Mre11, a known
interactor of Rad50 (41) (Fig. 2C, compare lane 1 with lane 3).
The N-terminal region of Rif2 is essential for its regulatory role
To gain a better understanding of how Rif2 attenuates the
MRX-dependent activation of Tel1, we sought to identify
the region of Rif2 responsible for its inhibitory role. The
extreme N-terminal region of Rif2 has been implicated in its
telomere length regulatory function in vivo (23, 37). This region
is predicted to be largely unstructured and lies outside of the
Figure 2. The Xrs2 subunit of MRX is dispensable for Rif2’s inhibitory
activity in vitro. A, standard kinase reaction with increasing concentrations
of Rif2, and 30 nM MR, RX, or MRX complex. A representative experiment is
shown. B, quantification of three independent experiments with S.E. The reac-
tion without Rif2 (lane 2) was set to 100. C, purified Rad50 subunit was incu-
bated with either GST-tagged Mre11, Rif2-WT, Rif2-F8A, Rif2 (1–170), or Rif2
(1– 60). The beads were washed and bound Rad50 was analyzed by 7% SDS-
PAGE, followed by Western blotting with anti-Rad50 antibody, exactly as
described (36). GST (lanes 2 and 4) was used as a negative control.
Rif2 inactivates the ATP form of MRX
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Orc4-homology domain (37). Specifically, the Rif2-F8A muta-
tion completely abrogated Rif2’s functionality in yeast (23).
This point mutant confers a similar telomere phenotype to that
of a rif2D mutant. We tested the F8A variant of Rif2 in our in
vitro system. Rif2-F8A showed no inhibition of the MRX-de-
pendent activation of Tel1 (Fig. 3, A and B). We carried out
several control experiments to test the integrity of the F8A
mutant. First, Rif2 shows a weak DNA-binding activity; this
activity is unaltered in the mutant (Fig. S3C). Second, the inter-
action between Rad50 and Rif2 is not affected by the F8A muta-
tion (Fig. 2C, lane 5). Furthermore, both the Rad50-Rif2 and
Rad50-Rif2F8A interactions are unaffected by the presence of
Mg-ATP in the assay (Fig. S2A). Therefore, the interaction
between Rif2 and Rad50 alone is not sufficient to mediate
inhibition.
We next queried whether the entire Rif2 protein is required
for inhibition. In yeast, the artificial tethering of Rif2 (1–170) to
telomeres via Tet-operator sites restored the regulatory func-
tion to a rif2 mutant (22). In an independent study, fusion of
Rif2 (1– 60) to Rap1, which ensures telomere localization by
artificial means, similarly restored telomere length control to
the rif2 mutant (23). In our in vitro assay, the GST-Rif2
(1–170) truncation showed comparable inhibition to full-
length GST-Rif2 (Fig. 3C, lanes 4 and 5), whereas the GST-Rif2
(1– 60) truncation showed low but detectable inhibition (50%,
lane 6). The weaker inhibitory activity of Rif2 (1– 60) compared
with Rif2 (1–170) and full-length Rif2 is consistent with the
decreased interaction between Rif2 (1– 60) with Rad50 (Fig. 2C,
compare lane 8 with lanes 6 and 7). Parenthetically, the extreme
N-terminal location of the essential Phe (at position 8 for most
Saccharomyces species, Table S1) might suggest that its mode
of action involves insertion of the entire N-terminal peptide
into a hydrophobic cavity of Rad50. However, in control exper-
iments, we show that the presence of the N-terminal GST-do-
main did not interfere with the function of Rif2 (Fig. 3C and Fig.
S3, A and B).
Finally, we tested whether the inhibitory function of Rif2
requires both MRX and DNA, even though the DNA-stimu-
lated Tel1 kinase activity is not inhibited by Rif2 (Fig. S1C). One
proposed model for the regulatory role of Rif2 is that Rif2
changes the DNA end-tethering properties of MRX (34). This
model can be tested because MRX stimulates the kinase activity
of Tel1 2- to 3-fold in the absence of DNA (Fig. 1B) (36). Rif2 or
Rif2-F8A was added to standard Tel1 kinase reactions contain-
ing MRX but no DNA. Rif2 inhibited the MRX-dependent
stimulation of Tel1 whereas the mutant was ineffective (Fig.
3D). Interestingly, the Tel1-catalyzed phosphorylation of
Mre11 and Xrs2 is not affected by Rif2. This result is consistent
with our previous observation that the phosphorylation of
these two subunits by Tel1 is largely constitutive (36).
Rif2, but not Rif2-F8A, stimulates the ATPase activity of MRX
It is important to make a distinction between ATP binding by
Rad50 and hydrolysis of the bound ATP (ATPase activity). Sev-
eral studies have shown that mutants that are deficient for ATP
binding are phenotypically similar to rad50 in checkpoint
activation and DNA repair (17, 36). However, ATP binding and
not its hydrolysis drives the activation of Tel1ATM kinase in the
complex with DNA and MRX(N) (42, 43). This raises the pos-
sibility that Rif2 acts by modulating the ATPase activity of
Figure 3. The N-terminal region of Rif2 is important for its inhibitory role. A, standard kinase reaction with increasing concentrations of either Rif2-WT or
Rif2-F8A. A representative experiment is shown. B, quantification of three independent experiments with S.E. Relative Tel1 activity of the reaction without Rif2
was set to 100 (lane 2). C, standard kinase assays contained 2 M indicated Rif2 or GST-Rif2 variants. D, standard kinase assays were carried out without DNA and
Rif2 as indicated. Reactions were incubated for 30 min. Bottom, averages and S.E. are derived from three independent experiments. The reaction without Rif2
(lane 1) was set to 100.
Rif2 inactivates the ATP form of MRX
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MRX. In fact, in one study, Rif2 was shown to stimulate the
ATPase activity of MRX by about 2-fold (34). Our own assess-
ment of the effect of Rif2 on the MRX ATPase activity recapit-
ulates this observation and extends it. Rif2 stimulated the
ATPase activity of MRX either in the absence (Fig. S4B) or the
presence of DNA (Fig. 4A). In contrast, Rif2-F8A showed no
detectable stimulation of the MRX ATPase (Fig. 4A and Fig.
S4B). Considering that none of the other activities of Rif2 is
altered in the F8A mutant (DNA binding, interaction with
Rad50), the most straightforward conclusion from these data is
that the increase in the ATPase of MRX is associated with loss
of Tel1-specific MRX activity.
To understand how Rif2 interferes with the MRX-mediated
activation of Tel1 through the Rad50 ATPase, we used an allos-
teric ATPase mutant of Rad50. Rad50(CC48) has two point
mutations (S685R, Y688R) and lacks an additional 104 amino
acids of the coiled-coiled domain near the zinc hook motif (Fig.
1B) (33, 44 –46). The rad50-CC48 mutant is defective for
Tel1-mediated checkpoint signaling in response to DNA dou-
ble-stranded breaks (33). In addition, the mutant has shortened
telomeres. In biochemical studies, the mutant MR(CC48)X
complex lacks ATPase activity (33). We surmise that the effects
of these mutations are allosteric in nature because they are dis-
tal from the conserved ATP-binding domains (Fig. 1B), and
indeed, the mutant MRX complex still binds ATP like WT (Fig.
4B). Consequently, the observation that this mutant complex
also activates Tel1 like WT was as expected (Fig. 4C, lanes 1 and
4). However, because the mutant showed little or no basal
ATPase activity, the observed inhibition by Rif2 was surprising
(Fig. 4C, lanes 2 and 5; Fig. S4A). Remarkably, we found that
Rif2, but not Rif2-F8A, caused a potent stimulation of the
MR(CC48)X ATPase activity (Fig. 4D). As observed with WT
MRX, the Rif2-stimulated ATPase activity of MR(CC48)X
does not require the presence of effector DNA (Fig. S4, B
and C).
A new model for Rif2-mediated regulation of Tel1 kinase
The Rad50(CC48) mutant has given us a unique window
into observing the regulatory function of Rif2. The ATPase
activity of WT MRX is stimulated about 2-fold by either DNA
or Rif2, and when both are present, the activity is additive (Fig.
4A and S4D). In contrast, the mutant MRX complex with or
without DNA shows limited ATPase activity (Fig. S4E). Yet,
with or without DNA, Rif2 causes a robust stimulation of its
ATPase (Fig. 4D and Fig. S4C). Under any of these conditions,
mutant Rif2-F8A does not affect the MRX ATPase. These data
suggest that the conformational/structural changes that occur
in MRX when the bound ATP hydrolyzes are principally differ-
ent whether DNA or Rif2 is the effector molecule.
One straightforward explanation for these observations that
we considered is that the physical association of MRX with Tel1
is disrupted by Rif2, but not by Rif2-F8A. However, no disrup-
tion of binding was observed (Fig. S2B), and perhaps that result
was not surprising, because Tel1 has been shown to interact
with each of the three MRX subunits (36). Given the difference
between Rif2 and Rif2-F8A, we propose that inhibition is a two-
step process. The first step involves binding of Rif2 to Rad50,
which does not require the critical Phe (Fig. 2C). In the second
step, the Phe-8 region of Rif2 likely alters the ATP-binding
pocket of Rad50, stimulating its hydrolysis, and possibly induc-
ing a conformational state of Rad50 that is competent for bind-
ing Tel1, but not productive for kinase stimulation. This pro-
posal is supported by the observation that several different




The DNA substrates used were a linearized 2 kb DNA (by
BamHI), derived from plasmid pUC19, a 147-mer natural DNA
sequence, derived from the Widom 601 sequence (50). The
155-mer yeast telomeric repeat sequence was derived from the
left arm of chromosome 4. The TG(1–3) repeats account for
155 bp. Terminal AflII restriction sites were used for cloning in
pUC19 and subsequent cleavage.
Protein expression and purification
Tel1, MRX, and MRX subcomplexes and Rad53-kd were puri-
fied as described (36). The MR(CC48)X mutant complex was
expressed in Sf9 cells, and purified on Xrs2-FLAG-affinity beads.4
Rap full-length and Rap1 (1–622) were purified as described (51).
The Rif2 WT gene was cloned in pGEX-6p-1 vector at EcoRI/
XhoI restriction sites and overexpressed in Rosetta2(DE3)-pL-
ysS as described for Rap1 (51). GST-Rif2 overexpression cells
were lysed by sonication in lysis buffer (50 mM sodium phos-
phate buffer, pH 7.3, 400 mM sodium chloride, 10% glycerol, 1
mM EDTA, 1 mM DTT, and 0.1 mM PMSF). Cells debris was
spun down, and 0.2% polyethyleneimine was added to the
supernatant. After centrifugation the supernatant was incu-
bated overnight with GSH-Sepharose 4 Fast Flow resin (GE
Healthcare). The resin was then extensively washed with lysis
4 M. Hohl and J.H. Petrini, submitted for publication.
Figure 4. Rif2 stimulates the ATPase activity of MRX. A, standard ATPase
assays with DNA and WT MRX contained either no Rif2 (black), 2 M Rif2 (red),
or Rif2-F8A (blue). Negative controls contained 2 M Rif2 (green) or Rif2-F8A
(gray), but no MRX. B, nitrocellulose filter binding assays of [-32P]ATP to WT
or mutant MRX, as described (36). Control, no MRX. Quantification of three
independent experiments with S.E. is shown. C, Tel1 kinase assays with 30 nM
MRX or M(Rad50CC-48)X and 2 mM Rif2 or Rif2-F8A as indicated. D, ATPase
reactions as in A, but with M(Rad50CC-48)X. The green Rif2 and gray Rif2-F8A
curves, minus MRX, are from the same data set as shown in A.
Rif2 inactivates the ATP form of MRX
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buffer and lysis buffer containing 1 M sodium chloride. GST-
Rif2 was finally eluted with 25 mM reduced GSH in lysis buffer
and dialyzed overnight against heparin buffer (25 mM Tris
buffer, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, and 1
mM DTT). The dialyzed protein was loaded on a Poros 50 HE
Heparin column (Life Technologies, Inc.) and eluted with hep-
arin buffer containing 300 mM NaCl. Rif2 WT was purified
using the same protocol, except that PreScission Protease was
added during dialysis against heparin buffer. Rif2F8A and
Rif2F8S were generated by standard site-specific mutagenesis
using the Rif2 gene cloned in the pGEX6p-1 vector as template.
Rif2F8A and GST-Rif2F8A, Rif2F8S and GST-Rif2F8S were
expressed and purified using the procedure reported above for
the Rif2 WT constructs. The Rif 2 truncation construct (1–170
and 1– 60) were expressed and purified similarly, except that
the GST tag was kept on the purified truncated proteins. All
Rif2 proteins were dialyzed against storage buffer (20 mM
HEPES, pH 7.4, 400 mM NaCl, 40% (v/v) glycerol, 0.5 mM
EDTA, and 1 mM DTT) and stored at 80 °C.
Tel1 kinase assay
The standard 10 l assay contained 25 mM HEPES-NaOH
pH 7.6, 80 mM NaCl, 7 mM Mg-acetate, 100 g/ml BSA, 1 mM
DTT, 50 M ATP, 0.05 Ci [-32P]ATP, 200 nM GST-Rad53-
kd, 30 nM MRX, and 10 nM Telo DNA. Reactions were initi-
ated with 5 nM Tel1 at 30 °C for 15 min, stopped with 4 l of
2.5 SDS-PAGE loading dye, boiled, and separated on 7%
SDS-PAGE gels. Gels were dried and exposed to a phosphor
screen (GE Healthcare). Deviations from the standard assay
are indicated in the legends to figures. Data were analyzed with
ImageQuant software and plotted using KaleidaGraph software.
ATPase assay
Standard 20 l ATPase reactions contained 50 M
[-32P]ATP, 100 nM MRX, and 10 nM linearized pUC19 DNA in
buffer containing 25 mM HEPES-NaOH, pH 7.6, 80 mM NaCl, 7
mM Mg-acetate, and 1 mM DTT. At indicated times at 30 °C, 5
ml aliquots were quenched in 1.5 l of 150 mM EDTA/1% SDS.
Radioactive ATP and ADP were separated by PEI-Cellulose
TLC and quantified as described in Ref. 36.
GST-pulldown and ATP-binding experiments
Pulldown experiments in Fig. 2C and Fig. S2, and ATP bind-
ing in Fig. 4B were performed exactly as described in Ref. 36.
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